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http://dx.doi.org/10.1016/j.ccr.2014.02.009SUMMARYWe devised a high-throughput, cell-based assay to identify compounds to treat Group3 medulloblastoma
(G3 MB). Mouse G3 MBs neurospheres were screened against a library of approximately 7,000 compounds
including US Food and Drug Administration-approved drugs. We found that pemetrexed and gemcitabine
preferentially inhibited G3 MB proliferation in vitro compared to control neurospheres and substantially in-
hibited G3 MB proliferation in vivo. When combined, these two drugs significantly increased survival of
mice bearing cortical implants of mouse and human G3MBs that overexpress MYC compared to each agent
alone, while having little effect onmouseMBs of the sonic hedgehog subgroup. Our findings strongly suggest
that combination therapy with pemetrexed and gemcitabine is a promising treatment for G3 MBs.INTRODUCTION
Medulloblastoma (MB), a tumor of the posterior fossa, is primar-
ily a pediatric disease, although it occasionally occurs in adults
(Ellison et al., 2011). MB is classified into four major subgroups
based on clinical and molecular profiles (Taylor et al., 2012).
Two subgroups exhibit constitutive activation of the sonic
hedgehog (SHH) or wingless (WNT) developmental pathways.
The other two are referred to as group 3 (G3) and G4. Impor-
tantly, the molecular subgrouping of these tumors also relates
to distinct patient demographics, histologic classification, so-
matic genetic variations, and clinical outcome. For example,Significance
Despite the recent identification of four molecular groups of hu
therapies independent of classification. G3MB has a high incid
therapeutic approaches for these patients are desperately nee
production of cultured neurospheres that provided an ideal pl
FDA-approved drugs that significantly inhibited mouse and h
xenografts from G3 MB primary patient samples, but not mou
combination therapy with pemetrexed and gemcitabine to tre
516 Cancer Cell 25, 516–529, April 14, 2014 ª2014 Elsevier Inc.patients with WNT MB tend to be older, female, and to uniformly
survive with current therapy (Northcott et al., 2012). In contrast,
patients with G3 MB tend to be younger, male, have anaplastic
histology, exhibit a higher incidence of metastatic disease, and
have a poor prognosis (Dubuc et al., 2013; Kool et al., 2012; Par-
sons et al., 2011; Pugh et al., 2012; Rausch et al., 2012; Robin-
son et al., 2012). One characteristic feature of G3 MB is their
high MYC expression in >75% of cases. Indeed, one study
shows that MYC expression is elevated in 20 of 26 (77%) G3
MBs (named groupC), compared to 1 of 35 (3%)G4MBs (named
group D; Northcott et al., 2011). Whole genome sequencing
studies on 17 G3 MBs reveals only one tumor (5.9%) with trueman MB, patients are currently treated with similar chemo-
ence of metastasis and poor prognosis. Thus, more effective
ded. The development of a mouse model of G3 MB enabled
atform to identify additional chemotherapies. We found two
uman G3 MB neurosphere cultures, mouse allografts, and
se SHH MBs. These findings provide a strong rationale for
at patients with G3 MB.
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rant copy number gain of the MYC gene. However, 15 of these
17 (88%) G3 MBs demonstrate high MYC expression (Robinson
et al., 2012). Despite these pronounced differences, patients
with MB are typically treated with uniform surgery, radiotherapy,
and adjuvant chemotherapy including vincristine, cisplatin, and
cyclophosphamide (Packer et al., 2013) or lomustine and carbo-
platin (Massimino et al., 2012). These therapies fail to cure one-
third of all patients and carry widespread morbidities that impair
survivor’s quality of life.
Molecular subgrouping has the potential to improve risk strat-
ification and tailor therapy to reduce toxicities to potential survi-
vors. Paramount to this strategy is the development of accurate
models that recapitulate the subgroups for preclinical therapeu-
tic testing. We developed a mouse model of G3 MB through
the orthotopic transplantation of transgenic cerebellar granule
neuronal progenitors (GNPs) in the cortices of naive recipient
animals. GNPs were purified by percoll density gradient from
the cerebella of 5- to 7-day-old Trp53/;Cdkn2c/ mice and
infected with retroviruses encoding MYC (Kawauchi et al.,
2012). MB tumors develop within 30 days of transplantation
with as few as 100 tumor cells that recapitulate the high level
of trimethylation of histone H3 at lysine 27 (H3K27me3) seen in
human G3 and G4 (Robinson et al., 2012). Tumors grow as neu-
rospheres that, when transplanted into cortices of recipient
mice, induce secondary MBs that mimic the primary tumors
(Kawauchi et al., 2012). Because neurospheres can be passaged
repeatedly while maintaining their functional and molecular
properties, they provide a unique platform to conduct screens
of compounds to identify thosewith therapeutic potential against
human G3 MB. We here report the outcome of screening a
library of compounds that included US Food and Drug Adminis-
tration (FDA)-approved drugs and candidate compounds in
development.
RESULTS
High-Throughput Screen Using Mouse G3 MB
Neurospheres
Tumor cells purified from several independently derived primary
mouse G3 MBs were grown as neurospheres for four to five
passages providing lines with comparable cell proliferation char-
acteristics. Two lines, derived from independent tumors and
infections, were hereafter referred to as ‘‘Myc1’’ and ‘‘Myc2.’’
Neurospheres from the cerebellum of 7-day-old (P7) Trp53/;
Cdkn2c/ mice (hereafter referred to as Trp53-null) were used
as control. To determine the number of cells necessary for expo-
nential growth 4 days after plating, mouse Trp53-null and Myc1
were plated at different densities (Figure S1A available online).
Other control cells included TERT human fibroblasts (BJ) to
identify compounds with nonspecific toxicities and HepG2
(a human hepatocellular carcinoma cell line) to eliminate highly
cytotoxic compounds.
We performed a primary screen of a ‘‘bioactive’’ library using a
luminescence-based assay that measures cell proliferation via
ATP. The library contained 7,389 compounds (6,568 unique) ob-
tained from different sources, including 830 FDA-approved
drugs (Figure S1B; see Supplemental Experimental Procedures
for details). Compounds were tested at a single concentration(10 mM) in triplicate. Z-prime and other assay diagnostics were
acceptable (Figure S1C) and the scatterplot of controls and
compound activities showed adequate separation between
signal and noise for both Myc1 and Trp53-null (Figure S1D,
left). Receiver operator characteristic analysis indicated that
the assay demonstrated acceptable discriminatory power be-
tween true-positive and true-negative results, with the area
under the curve (AUC) >0.8 for both lines, and that an assay cut-
off of >50% returned 70% of all true-positive results for Myc1
(Figure S1D, right). A total of 690 of the 7,389 compounds,
including all with inhibition >50% in the primary screen with
Myc1, analogs of these hits, and other compounds of interest,
were tested in dose-response experiments in triplicate using
concentrations ranging from 4 nM to 10 mM. Of the 690 hits,
we identified 65 compounds with potency <1 mM against Myc
1 (Figure 1; Table S1).
Screening Results of FDA-Approved Drugs
To accelerate the transition of potential therapeutics into the
clinic, we prioritized the FDA-approved drugs with oncology in-
dications and potencies below or near 1 mM for further study.
We conducted dose-response experiments on 35 FDA-
approved drugs in triplicate on Myc1, Trp53-null, HepG2, and
BJ cell lines (Figure S2A; Table 1). Drugs were grouped into
nine activity classes: folate pathway inhibitors, other inhibitors
of DNA/RNA synthesis, purine antimetabolites, microtubule in-
hibitors, sterol biosynthesis inhibitors, topoisomerase inhibitors,
epigenetic regulators, proteasome inhibitors, and RNA polymer-
ase inhibitors. Myc1 was extremely sensitive to folate pathway
inhibitors with pemetrexed, methotrexate, and raltitrexed being
the most selective. The DNA/RNA synthesis inhibitor gemcita-
bine was highly potent in both Myc1 and Trp53-null, but
achieved 100% efficacy in only Myc1. The purine antimetabolite
cladribine showed promising activity against Myc1, but a nar-
rower therapeutic window against the control cell lines HepG2
and BJ compared to other drugs. The proteasome inhibitor
bortezomib and the RNA polymerase inhibitor dactinomycin
were equipotent and equally efficacious against both Myc1
and Trp53 null. Microtubule inhibitors, including vincristine and
vinblastine, and topoisomerase inhibitors, such as doxorubicin,
etoposide, and topotecan, were active in G3 MB. Because they
are already used in the clinic for the treatment of MB, they were
not considered further. Cerivastatin and fluvastatin, two sterol
biosynthesis inhibitors targeting 3-hydroxy-3-methyl-glutaryl-
coenzyme A reductase, had high efficacy but low potency rela-
tive to the other compound classes. Decitabine, a drug that
causes both DNA damage and alterations in DNA methylation,
was moderately potent, and had much higher efficacy for
Myc1 over Trp53-null.
We selected decitabine, pemetrexed, and gemcitabine for
further study because of their selectivity and diversity in mecha-
nism of action. As noted earlier, mouse and human G3 MBs are
marked by a high level of H3K27me3. Decitabine is an S-adeno-
syl methionine and cytidine analog. At low dose and prolonged
exposure, decitabine targets DNA and histone methylation,
whereas it induces DNA damage at high doses (Figure 2A; Palii
et al., 2008). After 72 hr of treatment, the half-maximal effective
concentration (EC50) for decitabine was 1.3 mM against Myc1
with 100% efficacy (Figure S2A, blue curve; Table 1), whereasCancer Cell 25, 516–529, April 14, 2014 ª2014 Elsevier Inc. 517
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Table 1. EC50 Values for FDA-Approved Drugs on Myc1, Trp53-null, and Control Cell Lines
Compound Myc1 (mM) Trp53-null (mM) HepG2 (mM) BJ (mM)
Amsacrine 0.16 (0.097–0.27) 0.55 (0.18–1.7) 11 (5.6–23) 13 (7.6–21)
Ancitabine 0.031 (0.024–0.04) 0.55 (0.29–1) ND ND
Bortezomib 0.0063 (0.0051–0.0078) 0.0027 (0.0018–0.004) 0.026 (0.0076–0.087) 0.023 (0.0086–0.061)
Cerivastatin 0.77 (0.65–0.9) 2.5 (1.3–4.7) 0.92 (0.55–1.6) ND
Cladrabine 0.0043 (0.0024–0.0078) 0.25 (0.026–2.4) 3.3 (2.6–4.3) 1.4 (0.13–17)
Clofarabine 0.15 (0.13–0.18) 0.34 (0.28–0.4) ND ND
Cycloguanil 0.11 (0.059–0.21) 0.18 (0.14–0.23) ND ND
Cytarabine 0.083 (0.066–0.1) 0.2 (0.092–0.42) 0.078 (0.041–0.15)a ND
Dactinomycin 9e-04 (0.00016–0.005) 0.0024 (0.0012–0.005) 0.0084 (0.005–0.014) ND
Daunorubicin 0.0075 (0.0059–0.0097) 0.036 (0.016–0.079) 1.7 (0.11–25) 0.1 (0.02–0.52)a
Decitabine 1.3 (0.72–2.2) 0.032 (0.014–0.073)a ND ND
Doxorubicin 0.028 (0.015–0.052) 0.11 (0.058–0.2) 0.58 (0.14–2.3) 0.14 (0.027–0.77)a
Etoposide 0.24 (0.17–0.36) 0.046 (0.013-0.15) ND ND
Floxuridine 0.0016 (0.0013–0.002) 0.0001b ND ND
Fluorouracil 0.36 (0.3–0.43) 0.22 (0.17–0.29) ND ND
Fluvastatin 4.5 (1.6–13) ND ND ND
Gemcitabine 0.0021 (0.0018–0.0025) 0.00032 (0.00012–0.00087) ND ND
Lovastatin 4 (3.3–4.8) 2.1 (0.11–38)a 13 (4.7–38) ND
Methotrexate 0.0052 (0.0024–0.012) 0.15 (0.05–0.46) ND ND
Mitoxanthrone 0.18 (0.11–0.29) 0.19 (0.12–0.31) 0.12 (0.072–0.2)a ND
Nocodazole 0.11 (0.036–0.32) 0.094 (0.037–0.23)a 0.015 (0.0073–0.03)a ND
Pemetrexed 0.035 (0.027–0.046) 15 (0.57–410) ND ND
Pitavastatin 3.5 (1.5–8.6) ND 5 (2.8–8.7) ND
Podofilox 0.0064 (0.0015–0.028) 0.0074 (0.0048–0.012)a 0.0039 (0.0025–0.0059)a ND
Pyrimethamine 4.9 (3–8.1) 0.87 (0.2–3.9) ND ND
Raltiterxed 0.003 (0.0024–0.0038) 0.34 (0.18–0.63) ND ND
Rosuvastatin 2.6 (2.3–3) ND ND ND
Simvastatin 3 (2.6–3.5) ND 9.4 (6–15) 5.8 (4.7–7.2)
Tenoposide 0.052 (0.003–0.89) 0.11 (0.0097–1.2) 7.7 (1.5–39) 29 (3.8–230)
Thioguanine 0.44 (0.082–2.4) 0.8 (0.52–1.2) 11 (2.3–52) ND
Topotecan 0.075 (0.05–0.11) 0.18 (0.06–0.53) 0.09 (0.026–0.31) ND
Trifluridine 0.038 (0.034–0.043) 0.0029 (0.0022–0.0039) ND ND
Trimetrexate 0.035 (0.0028–0.45) 0.0047 (0.0033–0.0066) ND ND
Vinblastine 0.012 (0.0028–0.053) 0.015 (0.011–0.021)a ND ND
Vincristine 0.0094 (0.0044–0.02) 0.01 (0.0071–0.014)a ND ND
Concentration range in parentheses. ND, EC50 could not be determined in the concentration range tested.
aIndicates regression curve failed to reach 50% efficacy.
bIndicates questionable EC50 due to regression artifacts.
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red curve; Table 1). Treatment of Myc1 with 0.5 mM decitabine
for 72 hr significantly decreased H3K27me3 levels while 40 nM
of pemetrexed had no effect (Figure 2B).
A comparative study of gene expression profiles in mouse
G3 and SHH MBs and GNPs suggested that mouse G3 MBs
were sensitive to inhibitors of purine (Figure 2C, top), pyrimidineFigure 1. Summary of the HTS on Mouse Myc1 and Trp53-null Neuros
Distribution of 690 active compounds from dose response in Myc1 and Trp53-n
represented as a colored circle, with potency against Myc1 depicted by size a
selective for Myc1 are represented by large, blue circles.
See also Figure S1 and Table S1.(Figure 2C, middle), and folate (Figure 2C, bottom) metabolism
compared to SHH MBs and GNPs. In agreement with this gene
expression pattern, pemetrexed and gemcitabine targeted
these pathways. Pemetrexed targets three enzymes in the
folate pathway; phosphoribosylglycinamide formyltransferase
(GART), dihydrofolate reductase, and thymidylate synthase
(Figure 2D; Chattopadhyay et al., 2007). After 72 hr ofpheres
ull neurospheres according to their mechanism of action. Each compound is
nd potency against Trp53-null shown by blue-red color. Potent compounds
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Figure 2. Pattern of Sensitivity of Trp53-null and G3 Neurospheres to the Different Classes of Compounds
(A) An outline of the decitabine pathway.
(B) Detection of H3K27me3 by immunoblotting from cell lysates of Myc1 and Myc 2, untreated (C), or treated with decitabine (D) or pemetrexed (P). Ctrl,
recombinant human H3.
(C) mRNA levels of enzymes involved in purine (top), pyrimidine (middle) metabolism, and the folate pathway (one carbon pool and folate biosynthesis; bottom;
from KEGG pathway) between mouse G3 MB, SHH MB, and Trp53-null GNPs.
(D) Pemetrexed effects on the folate pathway: pemetrexed inhibits phosphoribosylglycinamide formyltransferase (GART), dihydrofolate reductase (DHFR), and
thymidylate synthase (TS).
(E) Gemcitabine targets: gemcitabine blocks DNA replication and deoxynucleotide triphosphate (dNTP) synthesis.
See also Figure S2.
Cancer Cell
Pemetrexed and Gemcitabine in G3 Medulloblastomapemetrexed treatment, the EC50 for Myc1 was 35 nM (Fig-
ure S2A, blue curve; Table 1), compared to 15 mM in Trp53-
null (Figure S2A, red curve; Table 1). Gemcitabine disrupts
DNA synthesis via incorporation in DNA or inhibition of the ribo-
nucleotide reductase (Figure 2E; van Moorsel et al., 2000).
When incorporated into DNA, gemcitabine causes single-
strand breaks that lead to apoptosis (Ewald et al., 2007). After
72 hr treatment, the Myc1 EC50 for gemcitabine was 2.1 nM
with 100% efficacy, whereas efficacy against Trp53-null never
exceeded 63% (Figure S2A; Table 1).
Decitabine, pemetrexed, and gemcitabine were further tested
on four additional mouse G3 MB lines derived from indepen-
dently derived tumors and infections; all displayed comparable
potency and efficacy compared to Myc1 (Figure S2B). In
contrast, we found a SHH MB-derived line was as sensitive to
pemetrexed as Myc1 but was greater than 5-fold less sensitive
to gemcitabine compared to Myc1 (Figure S2C).
Pharmacological Assessment of Decitabine,
Pemetrexed, and Gemcitabine on Mouse G3 MBs
To determine the concentration-time threshold required to inhibit
proliferation of neurospheres in vitro, we performed ’’wash-out’’
experiments with each of the three compounds. The EC50 values520 Cancer Cell 25, 516–529, April 14, 2014 ª2014 Elsevier Inc.for decitabine were approximately 2.4 mM, 920 nM, and 500 nM
after 1, 10, and 24 hr drug exposure, respectively (Figure 3A,
top). While the EC50 for pemetrexed was 1.2 mM after 1 hr expo-
sure, it decreased to 500 nM after 10 hr, and to 180 nM after 24 hr
(Figure 3A, middle). With gemcitabine, the EC50 values were
44 nM, 13 nM, and 3.8 nM after 1, 10, and 24 hr exposure,
respectively (Figure 3A, bottom).
Although decitabine affected the viability of Myc1 and
decreased H3K27me3 in vitro (Figure 2B), a review of the pub-
lished preclinical and clinical pharmacokinetic data (Chabot
et al., 1983; George et al., 2010) strongly suggested that the
maximally achievable decitabine brain concentrations in humans
would be well below those required to induce significant inhibi-
tion of proliferation. Therefore, decitabine was not considered
for further in vivo studies.
For gemcitabine and pemetrexed, total plasma and tumor
extracellular fluid (tECF) drug concentrations were assessed
in separate groups of mice bearing Myc1-induced G3 MB after
single intravenous (i.v.) injections of pemetrexed (200 mg/kg)
and gemcitabine (60 mg/kg). A three-compartment pharmaco-
kinetic model adequately described the plasma and tECF
concentration-time data for each drug. The murine plasma
pharmacokinetics for each agent differed only modestly from
Figure 3. Effects of Pemetrexed and Gemcitabine on Mouse and Human G3 Neurospheres In Vitro and Pharmacokinetics in G3 MB-
Bearing Mice
(A) In vitro ‘‘washout’’ of decitabine (top), pemetrexed (middle), and gemcitabine (bottom) on Myc1. Cells incubated with drugs for indicated times (1 hr, light blue
line; 3 hr, red line; 6 hr, dark blue line; 10 hr, brown line; 24 hr, gray line; 72 hr, black line) after which the medium was replaced by fresh medium and plates were
read 72 hr later. Error bars represent SD.
(B) Concentration-time plot for pemetrexed (top) and gemcitabine (middle). Observed tumor extracellular fluid concentrations (tECF; open squares), population
simulation of tECF concentration-time data (solid black line), and population simulation of total plasma concentration-time data (dotted line) included in both
plots. The horizontal dashed line represents the 1 hr EC50 derived from Myc1. PK parameters are described in the bottom (t1/2, half-life; pAUC, area under the
plasma concentration-time curve; and tECF/AUC, tumor extracellular fluid/AUC ratio). Values in the bottom represent averages ± SD.
(C) Neurospheres from two G3 MB PDXs, TB-12-5950 (light blue curves) and OA-2012-1 (dark blue curves), treated with concentrations from 1 nM to 10 mM of
pemetrexed and gemcitabine, and read 72 hr later; top, pemetrexed EC50 = 160 nM (light blue line) or 100 nM (dark blue line); bottom, gemcitabine EC50 = 5.1 nM
(light blue line) or 11 nM (dark blue line).
See also Figure S3.
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and pemetrexed being approximately 2-fold higher in our
studies (Rocchetti et al., 2007; Wang et al., 2004; Woodland
et al., 1997). The plasma exposure of each drug, quantified
by the area under the plasma concentration-time curve
(pAUC), was similar to that achieved in humans at clinically
relevant dosages (Figure 3B, upper and middle; Malempati
et al., 2007; Reid et al., 2004). We found that the tECF con-
centrations of pemetrexed and gemcitabine exceeded the
in vitro EC50 versus time threshold, suggesting that these com-
pounds should have in vivo efficacy in G3 MB (Figure 3B,
bottom).
To address how much drug crosses the normal blood-brain
barrier, studies of pemetrexed and gemcitabine were con-
ducted in six non-tumor-bearing mice. Pemetrexed (200 mg/
kg i.v.) or gemcitabine (60 mg/kg i.v.) was administered, the
brain was harvested, and the drug concentration was mea-
sured in the brain parenchyma and in the plasma. The
brain-to-plasma ratio of pemetrexed and gemcitabine in
these samples was 7.3% and 45%, respectively, indicating
that both drugs cross a normal blood-brain barrier in a mouse
model.Pemetrexed and Gemcitabine Inhibit Human G3 MB
Proliferation In Vitro
To assess whether pemetrexed and gemcitabine inhibited prolif-
eration of human G3 MB in vitro, we generated patient-derived
xenografts (PDXs) from primary G3 MBs overexpressing the
MYC protein with or withoutMYC amplification and derived neu-
rospheres for two of them. Gene expression profiling of Icb-1572
(Zhao et al., 2012) and TB-12-5950 (St. Jude Children’s
Research Hospital [SJCRH]) confirmed clustering with previ-
ously published human G3 MB (Robinson et al., 2012), and
demonstrated that a similar profile was maintained through
several passages in mice (Figure S3A). Fluorescence in situ hy-
bridization analysis revealed that MYC was not amplified in
Icb-1572 (Figure S3B, left; Shu et al., 2008) but was amplified
in TB-12-5950 that also displayed leptomeningeal dissemination
(Figure S3B, right). PDX OA-2012-1 overexpressed the MYC
protein without amplification, as measured by aCGH (O.A., un-
published data), whereas PDX Med-511-FH was confirmed to
have MYC amplification by nanostring analysis (J.M.O., unpub-
lished data).
TB-12-5950, OA-2012-1, and human neural stem cells H9
formed neurospheres in vitro, allowing us to test the effects ofCancer Cell 25, 516–529, April 14, 2014 ª2014 Elsevier Inc. 521
Figure 4. In Vivo Efficacy of Pemetrexed
and Gemcitabine against G3 MBs
Mice injectedwith luciferasemarked 13 105Myc1
(A–D) or 13 106G3MBPDX cells (E–G). Treatment
was initiated when luciferase signal reached 5.105
photons/sec. Luciferase measurements (left), sur-
vival (right).
(A) Top: mice treated at day 2 (green arrow) with
pemetrexed (green bars and line) or saline (black
bars and line). Bottom: mice treated at days 2 and
9 with pemetrexed (green arrows). n = 10 drug
treatment, n = 5 saline.
(B) Mice treated at days 2 and 9 (blue arrows) with
gemcitabine (treated group, blue bars and line) or
saline (control group, black bars and line). n = 10
drug treatment, n = 5 saline.
(C) Top: mice treated at days 2 and 9 (red arrows)
with pemetrexed and gemcitabine administered
together (treated group, red bars and line) or
saline (control group, black bars and line). Bottom:
mice treated with gemcitabine at days 5 and 12
(blue arrows) and pemetrexed at days 7 and 14
(green arrows; treated group, red bars and line) or
saline (control group, black bars and line). n = 10
treated group, n = 5 control group.
(D) Long-term treatment of Myc1-bearing mice with vehicle (black bars and line), or treated (red bars and line) with pemetrexed (green arrows) and gemcitabine
(blue arrows).
(E) Mice bearing G3 MB PDX Icb-1572 (passage 8) treated at day 13 after implant and days, 20, 34, and 41 (red arrows) with pemetrexed and gemcitabine (n = 5,
red bars and red line) or saline (n = 5, black bars and black line).
(F) Mice bearing G3MB PDX TB-12-5950, treated after implant at days 40, 47, 61, and 68 (red arrows) with pemetrexed and gemcitabine (n = 5, red bars and line)
or saline (n = 5, black bars and line).
(G) Mice bearing G3 MB PDX Med-511-FH treated at days 26, 33, 47, and 54 (red arrows) with pemetrexed and gemcitabine (n = 5, red bars and line) or saline
(n = 5, black bars and line). Error bars represent SD.
See also Figure S4.
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Pemetrexed and Gemcitabine in G3 Medulloblastomapemetrexed and gemcitabine in vitro. Neurospheres were
treated for 72 hr at doses ranging from 1 nM to 10 mM. Cell
viability was measured. For TB-12-5950 and OA-2012, EC50
for pemetrexed were 160 nM and 100 nM (Figure 3C, top),
whereas those for gemcitabine were 5.1 nM and 11 nM, respec-
tively (Figure 3C, bottom). These EC50 values were similar to
those found for Myc1 (within 2- to 5-fold; Table 1). For H9 cells,
the EC50 for pemetrexed was 0.29 mM and for gemcitabine
0.0015 mM (Figure S3C), which corresponded to the response
seen in mouse control Trp53-null (Figure S2A, Table 1).
Pemetrexed and Gemcitabine Activity in Mouse G3 MBs
In Vivo
To determine how efficacious pemetrexed and gemcitabine
were in suppressing proliferation of mouse G3 MB in vivo, we
stereotactically transplanted 1 3 105 purified tumor cells, retro-
virally transduced with luciferase, in the cortices of CD1 mice.
We previously determined that this cell number induces MBs
that kill the animals within 15 days after transplant and recapitu-
late the primary tumors (Kawauchi et al., 2012). Bioluminescence
detection of tumor progression correlated with tumor volume
measured with magnetic resonance imaging (Figures S4A–
S4C). Hematoxylin and eosin (H&E) staining of tumor sections
performed 3 days after transplant confirmed the presence of
an organized tumor mass that was vascularized and surrounded
by blood vessels (Figure S4D).
The schedule and dosage of drug delivery was calculated
based upon modeling and simulation of data from our pharma-522 Cancer Cell 25, 516–529, April 14, 2014 ª2014 Elsevier Inc.cokinetic studies, and related to pAUC values tolerable in pedi-
atric clinical trials (Malempati et al., 2007; Reid et al., 2004).
Mice transplanted with Myc1 were treated by tail vein injection
with 200 mg/kg pemetrexed (Figure 4A), 60 mg/kg gemcitabine
(Figure 4B), or a combination of both drugs (Figure 4C). When
combined, pemetrexed and gemcitabine were either given
together in the same injection (Figure 4C, top) or split by a
2-day interval (first gemcitabine, 2 days later pemetrexed; Fig-
ure 4C, bottom) to reduce stress on the mice.
Five mice treated with vehicle survived up to 14 to 20 days
after transplant, as expected (Figures 4A–4C, black bars). One
dose of pemetrexed at day 3 increased median survival by
3 days (Figure 4A, top). Mice treated with two doses of peme-
trexed at days 3 and 10 had an increased 7-day median survival
(Figure 4A, bottom). Two doses of gemcitabine at 60 mg/kg, at
days 2 and 9 after tumor implant, had an 11-day increased
median survival compared to mice treated with vehicle (Fig-
ure 4B). Treatment of mice with the two drugs given at the
same time on days 2 and 9 increased their median survival by
13 days compared to vehicle-treated animals (Figure 4C, top).
Similarly, mice treated with gemcitabine at days 5 and 12 and
with pemetrexed at days 7 and 14 (Figure 4C, bottom) had a
12-day increase in median survival (from 18 to 30 days). There-
fore, mice receiving both drugs together or separately had a
similar increased median survival compared to vehicle-treated
animals.
We repeated the efficacy studies with Myc2 and obtained
similar results (Figure S4E). The survival of animals treated with
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days 4 and 11 increased the median survival up to 28 days.
Mice treated with gemcitabine at days 4 and 11 had a median
survival of 26 days whereas cotreatment with pemetrexed and
gemcitabine given together increased the median survival by
33 days (Figure S4E).
Because the treatment of mice with the two drugs adminis-
tered singly or together was well tolerated, based on weekly ob-
servations of signs of morbidity (loss of motion, head dome, and
lethargy) and white blood cell count, and because the tumors re-
turned despite treatment, we assessed the effects of a longer
treatment course on tumor growth. Ten Myc1-induced G3 MB-
bearing mice were either treated with vehicle or once a week
with gemcitabine from days 4 to 32 and pemetrexed from days
6 to 34 after tumor implant. Long-term treatment increased
mouse median survival by 18 days (Figure 4D). Similar results
were obtained when mice were transplanted with Myc2, and
treated long term with the two drugs administered together
(Figure S4F).
Pemetrexed and Gemcitabine Inhibit Human G3 MB
Proliferation In Vivo
The PDX Icb-1572, passage 8, was marked with luciferase and
implanted in the cortex of CD1 mice that were treated 13 days
after tumor implant with pemetrexed and gemcitabine at days
13, 20, 34, and 41 (Figure 4E). When added together, the two
drugs increased mouse median survival by 21 days. We
confirmed these results in two other G3 MB PDXs, with MYC
amplification, TB-12-5950, passaged once in NSG and three
times in CD1 mice and Med-511-FH, passaged once in NSG
animals (J.M.O., unpublished; Figures 4F and 4G). Because
each PDX had a different proliferation rate, treatment was initi-
ated at different times after implant when the luminescence
signal reached 5 3 105 photons/sec (TB-12-5950, 40 days [Fig-
ure 4F] and Med-511-FH, 26 days [Figure 4G; Figure S4G]). In
both cases, all mice treated with vehicle died of tumor burden
with a median survival of 67 days after implant whereas those
treated with gemcitabine and pemetrexed survived longer—up
to 81 days. Thus, for each PDX, the median survival was signifi-
cantly longer in the treatment group than in the control.
Effects of the Treatment ofMouseG3 and SHHMBswith
Pemetrexed and Gemcitabine Combined to Cisplatin
and Cyclophosphamide In Vivo
In an attempt to compare the pemetrexed and gemcitabine com-
bination to agents already in clinical use, we treatedmice bearing
mouseG3MBwith cisplatin and cyclophosphamide (cycle A) fol-
lowed with pemetrexed and gemcitabine (cycle B; Figure 5A;
White and Sterling-Levis, 2008). Vincristine, the third drug used
in the clinic, could not be used due to intolerable toxicity in
mice (data not shown). Mice treatedwith vehicle had to be eutha-
nized 21 days after implant (Figure 5B, black bars and lines).Mice
treated for two cycles with pemetrexed and gemcitabine com-
bined (cycle B) had an 18-day increased median survival
compared to vehicle-treated mice (Figure 5B, green bars and
line; p = 0.035). Mice treated with i.v. cisplatin, 5 mg/kg at day
1 and intraperitoneally with cyclophosphamide, 130 mg/kg for
5 consecutive days, days 2–6, had a median survival of 12 days
longer than the vehicle-treated mice (Figure 5B, blue bars andline; p = 0.035); however, two of the five mice died from acute
drug-induced toxicity. Remarkably, mice treated with cisplatin
and cyclophosphamide alternating with pemetrexed and gemci-
tabine survived 25 days longer than the vehicle-treated animals
but still succumbed to tumors (Figure 5B, red bars and line; p =
0.0069). Therefore, the combination of cisplatin and cyclophos-
phamide with pemetrexed and gemcitabine resulted in a longer
median survival than either treatment alone.
We evaluated the potential toxicity of each therapeutic
regimen by analyzing blood chemistries, including while blood
cells, absolute neutrophil and platelet counts, once a week
from cohorts of animals bearing mouse G3 MB treated with
cisplatin and cyclophosphamide (Figure 5C, blue lines), peme-
trexed and gemcitabine (Figure 5C, green lines), versus the com-
bination of both cycles (Figure 5C, red lines). One cycle of
cisplatin and cyclophosphamide dramatically decreased the
number of white blood cells, neutrophils, and platelets, but this
was reversible because the values recovered to normal once
treatment was stopped (Figure 5C).
To assess whether the combination of pemetrexed, gemcita-
bine, and/or cisplatin and cyclophosphamide could also sup-
press proliferation of human G3 MB and mouse SHH MB, tumor
cells purified from Icb-1572 and from a mouse SHH MB marked
with luciferase were implanted in the cortex of recipient CD1
mice. Animals were treated with the same regimen as for mouse
G3 MB. Mice bearing the Icb-1572 tumor died at 39 days post-
implant when treated with vehicle (Figure 5D, black line). When
treated with two rounds of cycle A, they died at 55 days (Fig-
ure 5D, blue line), but survive up to 60 days with two rounds of
cycle B (Figure 5D, green line). Mice treated with cycle A and B
died 63 days after transplant (Figure 5D, red line). Mice with
mouse SHH MB treated with vehicle had to be sacrificed
28 days after transplant (Figure 5E). Mice treated for two rounds
of cycle B had a 2-day increased median survival compared to
vehicle-treated mice (Figure 5E, green bars and line) but when
treated with two rounds of cycle A survived 14 days longer
than vehicle-treated mice (Figure 5E, panels, blue bars and
line). Finally, mice treated with alternating cycle A and B survived
8 days longer than the vehicle-treated animals but succumbed to
tumors (Figure 5E, red bars and line). This demonstrated that
treatment with pemetrexed and gemcitabine had little effect on
the survival of mice bearing mouse SHH MB. However, SHH
MBs responded to cisplatin and cyclophosphamide, as ex-
pected from clinical experience.
Resistance to Pemetrexed and Gemcitabine
In all cases, tumors relentlessly regrew and eventually killed the
animals. To test whether tumor regrowth could potentially be due
to intrinsic drug resistance, tumor cells were purified from four
G3 MBs, two from untreated animals (tumors 1 and 2) and two
from mice treated with pemetrexed and gemcitabine (tumors 3
and 4; Figure 4D), and grown as neurospheres in the presence
or absence of drugs (Figure 6A). Regardless of whether the tu-
mor cells came from untreated or treated animals, they had
similar sensitivity to pemetrexed and gemcitabine, suggesting
that tumor regrowth was not due to intrinsic resistance to either
drug (Figure 6A). Moreover, gene expression analysis of tumors
harvested at sacrifice from treated or control mice showed no
significant difference in their global transcriptome; principalCancer Cell 25, 516–529, April 14, 2014 ª2014 Elsevier Inc. 523
Figure 5. Treatment of Mouse G3 and SHH MBs with Pemetrexed and Gemcitabine Combined with Cyclophosphamide and Cisplatin
(A) Treatment schedule with cisplatin (C, bold blue arrow) at day 1 and cyclophosphamide (C, dark blue arrows) from days 2 to 6 every 3 weeks (C+C, cycle A, top)
or pemetrexed and gemcitabine together twice every 3 weeks (P+G, cycle B, bottom).
(B) Mice bearingmouse G3MB treated with saline (black bars and line), C+C at each course, (blue bars and line), P+G at each course (green bars and line), or with
C+C for the first course and P+G for the second course (red bars and line). Error bars represent SD.
(C)White blood cells (WBC), neutrophils (ANC), and platelet counts for mice treatedwith saline (black curves), C+C at each course (blue curves lines), P+G at each
course (green curves) or alternative cycle of C+C first followed by P+G (red curves). Error bars represent SD.
(D) Mice bearing G3 MB PDX Icb-1572 treated with saline (black bars and line; median survival 39 days), with C+C at each course (blue bars and curve; median
survival 55 days, p = 0.0724), with P+G at each course (green bars and curve; median survival 60 days, p = 0.0084), or with C+C for the first course and P+G for the
second course (red bars and curve; median survival 62 days, p = 0.0044). Error bars represent SD.
(E) Mice bearing mouse SHH tumors treated with saline (black bars and line; median survival 28 days), with C+C at each course (blue bars and curve; median
survival 42 days, p = 0.045), with P+G at each course (green bars and curve;median survival 30 days, p = 0.1042), or with C+C first course and P+G second course
(red bars and curve; median survival 36 days, p = 0.040). Error bars represent SD.
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untreated animals or from G3 MBs treated with pemetrexed,
gemcitabine, or both, clustered together (Figure 6B).
To gage whether mouse G3 MBs harvested from animals
treated long-termwith pemetrexed and gemcitabine (Figure S4F)
remained sensitive to the two drugs in vivo, tumor cells were
purified from G3 MBs from treated mice at euthanasia and re-
implanted into the cortices of naive recipients. Mice bearing
MB were either left untreated (Figure 6C, black bars and line)
or treated with the two drugs added together, once a week
from days 6 to 34 (Figure 6C, red bars and line). Whether the tu-
mors were from animals treated or not, mouse median survival
was similar (compare Figure 6C to Figure S4F). To assess the
role of pharmacokinetics in drug resistance, mice bearing G3
MB were treated with pemetrexed and gemcitabine at days 3,
10, and 24. Plasma and brain samples were collected 1, 3, and
6 hr after the last day 24 treatment. Plasma exposure of both
pemetrexed and gemcitabine were equivalent to that observed
after single-dose treatment, and brain concentrations remained
above the respective EC50 concentrations for both drugs. These
results suggest that neither intrinsic acquired drug resistance of
tumor cells nor altered drug delivery accounted for the observed
persistent tumor growth after therapy.524 Cancer Cell 25, 516–529, April 14, 2014 ª2014 Elsevier Inc.Others have shown that the spatial distribution of chemother-
apeutics in solid tumors is highly dependent on the presence of
blood vessels (Minchinton and Tannock, 2006; Saggar et al.,
2013). Two independently derived mouse G3 MBs were immu-
nostained with an antibody to caspase 3 after treatment with
pemetrexed and gemcitabine. Caspase 3 staining was not de-
tected in the vehicle-treated tumors (Figure S5A, control) but
was found in tumors from treated mice. Even though tumors
were well vascularized, areas of apoptosis were detected (Fig-
ure S5A). Moreover, we found that pemetrexed and gemcitabine
induced cell death in tumor cells in vitro by Annexin V staining
(Figure S5B) and that gemcitabine induced histone 2AX (H2AX)
foci after 1 hr treatment at 5 nM (Figure S5C, bottom). Prolifera-
tion measured by bromo-deoxy-uridine (BrdU) incorporation
was similar in treated and untreated MBs (Figure S5D). These
data suggest that host factors and/or vascularization of the tu-
mors may limit the efficacy of pemetrexed and gemcitabine.
Purine metabolism is directly linked to the folate pathway
through the action of GART. We found that increasing the con-
centration of folate in the medium (up to 10 mM) significantly
decreased the sensitivity of mouse G3 MB neurospheres to
pemetrexed, highlighting the importance of the folate pathway
in these tumors (Figure S5E). We also noticed that when G3
Figure 6. Resistance of Mouse G3 MBs to Gemcitabine and Peme-
trexed Treatment
(A) Viability of tumor cells purified from four individual tumors (1–4) from ani-
mals treated in Figure S4F grown in vitro and treated with 40 nM pemetrexed
(pem, white bars), 5 nM gemcitabine (gem, gray bars), or both drugs together
(black bars). Cell viability was measured after 72 hr treatment by trypan blue
normalized to cells treated with DMSO. Error bars represent SD.
(B) Principal component analysis (PCA) for G3 neurospheres (G3 NS, black and
gray dots, n = 7), Trp53-null neurospheres (NS, clear blue dots, n = 3), primary
G3 MBs (dark blue dots, n = 3), secondary G3 MBs (yellow dots, n = 3), or G3
MBs (tumors) from animal treated with pem (orange dots, n = 3), gem (red dots,
n = 3) or both drugs (dark red dots, n = 3).
(C) Mice implanted with tumors harvested frommice treated in (A) were treated
with vehicle (black bars, top; black line, bottom) or with pem and gem com-
bined (red bars, top; red line, bottom) at days 7, 14, 28, and 35 (red arrows).
Error bars represent SD.
See also Figure S5.
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mide or pemetrexed/gemcitabine for one cycle, tumor cells har-
vested from these mice responded to the four drugs similarly in
culture with no significant differences in EC50 (Figure S5F).
DISCUSSION
G3 MB, characterized by high levels of MYC expression due to
gene amplification or overexpression (Northcott et al., 2011,
2012), is a particularly aggressive tumor for which current ther-
apy is inadequate. The generation of a MYC-driven murine
model of G3 MB and its propagation as robust neurospheres
enabled the testing and identification of compounds from a
‘‘bioactive’’ library including 830 FDA-approved drugs, to select
and prioritize agents for clinical development. The integration of
this in vitro drug screen with in vivo pharmacokinetic and phar-
macodynamic studies identified two FDA-approved drugs, pe-
metrexed and gemcitabine, as therapy for this deadly disease.
Overall, the screening process identified all expected drugs
known to have clinical effect including vincristine, vinblastine,
and etoposide (cisplatin and cyclophosphamide were not tested
due to incompatibility with the high-throughput screen [HTS]) as
well as agents not previously known to be active. Among the
latter category, decitabine was a very interesting ‘‘hit’’ becauseits use in vitro resulted in a decrease of H3K27me3, an epigenetic
mark characteristic of G3 and G4 MBs (Dubuc et al., 2013; Rob-
inson et al., 2012). Unfortunately, it was unsuitable for further
in vivo studies due to predicted inadequate central nervous sys-
tem exposure in humans. Nonetheless, the in vitro efficacy of
decitabine suggested that similar hypomethylating drugs with
adequate brain penetration should be considered for the
treatment of G3 MBs. On the other hand, pemetrexed and gem-
citabine showed high antiproliferative potency against mouse
and PDX G3 MBs in vitro and in vivo. When used as single
agents, each inhibited proliferation of mouse and human G3
MB neurospheres. When administered in combination to mice
bearingmurine or PDXsG3MB, survival time doubled compared
to vehicle-treated animals. In contrast, mouse SHH MBs did
not respond to the combination of pemetrexed and gemcitabine,
suggesting that the combination of the two drugs should
specifically target G3 MBs. It would be informative to know
whether this combination chemotherapy has a similar efficacy
in G4 MBs. However, if the response to the drugs is MYC
driven, then average lower levels of MYC expression in G4 MB
(Northcott et al., 2011) suggest that it will not be an effective ther-
apeutic approach. Furthermore, the large number and heteroge-
neity of G4 MBs, without the availability of several adequate
mouse models, preclude comprehensive preclinical studies
similar to those that cover the spectrum of G3 MB with MYC
overexpression.
Previous reports suggested that the combination of gemcita-
bine and pemetrexed was synergistic (Adjei, 2002; Tonkinson
et al., 1999), which prompted their use in the treatment of
non-small-cell lung cancer (NSCLC), pancreatic cancer, and
advanced breast cancer (Monnerat and Le Chevalier, 2006).
Clinical trials in adults have shown this combination of drugs to
be well tolerated for multiple cycles at doses of gemcitabine
ranging between 1,250 and 1,500 mg/m2 on days 1 and 8 and
of pemetrexed at 500 mg/m2 on day 8. Response rates have
been promising in the range of 10% to 44% in NSCLC. Further-
more, a number of clinical trials have tested different delivery
schedules of pemetrexed and gemcitabine, alternating the
administration sequence and intervals between administration
(Ma et al., 2005; Monnerat and Le Chevalier, 2006).
Both pemetrexed and gemcitabine have been used to treat
pediatric cancers with each agent exhibiting an acceptable
toxicity profile. A phase 1 pediatric clinical trial conducted in chil-
dren with refractory solid tumors evaluated a range of peme-
trexed dosages from 400 to 2480 mg/m2, and identified a
maximum tolerated dose (MTD) in children of 1,910 mg/m2 i.v.
given once every 21 days with folate and B12 supplementation
(Malempati et al., 2007). The results of a pediatric phase 1 study
with gemcitabine as single agent showed that the MTD was
1,200 mg/m2 when given as a 30 min infusion once weekly for
3 consecutive weeks of a 4-week cycle. The MTD for a 2-week
schedule has not been established; however, the dose escala-
tion concluded at 2,100 mg/m2 given on days 1 and 8 without
reaching a defined MTD, indicating that this regimen was well
tolerated (Reid et al., 2004).
Our studies in mice bearing G3 MB clearly showed that both
gemcitabine and pemetrexed exceeded their respective EC50
values in the tECF and studies in mice not bearing tumor showed
that both drugs penetrated the brain. This finding is consistentCancer Cell 25, 516–529, April 14, 2014 ª2014 Elsevier Inc. 525
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Kumthekar et al., 2013) in other animal models and humans
that showed modest, but clinically relevant brain penetration of
both gemcitabine and pemetrexed.
Our preclinical studies suggest that both pemetrexed and
gemcitabine are efficacious on mouse G3 MB when given
7 days apart, and we observed no difference in efficacy when
gemcitabine preceded pemetrexed or when administered
together. The plasma AUC values for pemetrexed (200 mg/kg/
dose) and gemcitabine (60 mg/kg/dose) in mice were similar to
those reported in humans at dosages in the 400–670 mg/m2
ranges for pemetrexed and 1,250 mg/m2 for gemcitabine (Mal-
empati et al., 2007; Reid et al., 2004). This suggested that the
combination of pemetrexed and gemcitabine was clinically
feasible at dosages well below the already established MTD in
children.
The comparison of pemetrexed and gemcitabine in combina-
tion to themore clinically analogous combination of cisplatin and
cyclophosphamide led to the unexpected finding that the inte-
gration of these four drugs produced a heightened tumor
response. We assessed the effect of cisplatin and cyclophos-
phamide alone, pemetrexed and gemcitabine alone, or a combi-
nation of those drugs. Whereas treatment with pemetrexed and
gemcitabine or cyclophosphamide and cisplatin increased the
median survival of mice bearing murine G3 MB by 18 and
12 days, respectively, versus vehicle treated animals, when
given as alternating cycles, median survival was increased by
25 days. Moreover, no additional toxicity was detected. When
transplanted with the PDX Icb-1572, the combination of the
two cycles led to an increased median survival of 23 days. In
contrast, treatment of mice bearing mouse SHH MB with cycles
of pemetrexed, gemcitabine, and cisplatin and cyclophospha-
mide did not improve mouse survival compared to treatment
with cisplatin and cyclophosphamide alone. These results pro-
vide stronger rationale for adding pemetrexed and gemcitabine
to the current therapeutic regimen for the treatment of human
G3 MBs.
Folates are essential for purine and pyrimidine synthesis and
consequently rapid cellular division and proliferation of cancer
cells. Gene set enrichment analysis confirmed that both the
folate and purine metabolic pathways were significantly en-
riched in mouse G3 MBs compared with GNPs and SHH MBs.
Although the antifolate agents methotrexate and 5-fluorouracil
have been widely used for decades in the treatment of malig-
nant tumors, pemetrexed is a relatively new therapeutic agent
currently approved as a first line treatment for mesothelioma
(Dowell et al., 2012), NSCLC in association with platinum-based
chemotherapy (Mubarak et al., 2012), and in newly diagnosed
brain metastasis (Bailon et al., 2012). It also showed clinical ac-
tivity in other adult tumors such as breast, colorectal, bladder,
cervical, gastric, and pancreatic cancers (Adjei, 2004; Chatto-
padhyay et al., 2007; Warwick et al., 2013). Genes regulating
pyrimidine metabolism were also enriched in mouse G3 MBs
compared with mouse GNPs and SHH MBs, in agreement
with the antiproliferation effects of gemcitabine, a pyrimidine
cytidine analog.
In summary, our studies identified gemcitabine and peme-
trexed, two FDA-approved drugs, as efficacious in increasing
survival of mice bearing PDX G3 MBs in which MYC is overex-526 Cancer Cell 25, 516–529, April 14, 2014 ª2014 Elsevier Inc.pressed. In combination with two chemotherapeutic drugs in
current clinical use, cyclophosphamide and cisplatin, we found
increased prolonged survival of mice bearing eithermouse or hu-
man G3MB for as long as 40 days after tumor implant compared
to untreated animals. Pemetrexed and gemcitabine have both
been evaluated in single agent phase 1 studies in childhood cen-
tral nervous system and solid tumors, and are recommended in
phase 2 clinical trials, although there are very limited data spe-
cific to MB. Due to the specificity of this combination therapy
in G3 over SHH MBs that harbor high MYC levels and have a
worse prognosis, it seems prudent to evaluate this therapy in hu-
man G3 MBs. G3, MYC amplification or overexpression, pres-
ence of metastatic disease, and large cell/anaplastic MBs are
all overlapping poor prognostic features of MB that represent a
huge challenge to the clinical management of the disease
because as a group these have an approximate 60% 5-year
overall survival in comparison to an 80% 5-year overall survival
in patients who do not harbor these characteristics. Further-
more, the majority of these patients currently get maximal
‘‘high risk’’ therapy, which includes high-dose craniospinal radi-
ation and adjuvant postradiation chemotherapy. Current and
future protocols are risk-stratifying patients based on the pres-
ence or absence of these and other molecular characteristics.
However, without having any additional effective agents to add
to high-risk therapy, there will be little change to these patients’
overall survival times.
These data are exciting from a clinical perspective because
they suggest that pemetrexed and gemcitabine can be added
to currently used chemotherapy with an enhanced effect and
little additional myelosuppressive toxicity. Therefore, these
medications, which have already been used clinically in combi-
nation with other chemotherapy regimens in other cancers,
could be incorporated into high-risk MB therapy for patients
with G3 MBs. We do not know whether the combination of pe-
metrexed and gemcitabine will be effective in G3 MBs that do
not overexpress or amplify MYC. However, because approxi-
mately 17% of G3 MB amplify the MYC gene (Northcott et al.,
2012), and >75% of G3 MB exhibit high MYC expression (North-
cott et al., 2011), this supports our recommendation to try this
therapy in G3 MB. These agents must be introduced in strin-
gently designed clinical trials that can strictly monitor for ex-
pected and unexpected toxicities of these agents as well as
measure whether the suggested enhanced effect of this therapy
translates to human disease.
EXPERIMENTAL PROCEDURES
Development of Mouse G3 and SHH MB and G3 MB PDXs
Mouse G3 MBs were generated by orthotopic transplantation of GNPs from
cerebella of P7 Trp53/; Cdkn2c/mice infected with MYC-encoding retro-
viruses (Kawauchi et al., 2012). Mouse SHH MBs spontaneously occur in
Ptch1+/; Trp53/ animals (Wetmore et al., 2001) and were previously
described (Uziel et al., 2005). G3 MB PDXs were developed from primary
tumor samples, from previously untreated patients, and implanted into the cor-
tex or cerebella of NSG mice. The generation of PDXs is provided in detail in
the Supplemental Experimental Procedures. In all cases, primary human brain
tumor specimens were obtained under written informed consent approved by
the Institutional Review Boards of SJCRH; the Necker Sick Children’s Hospi-
tal, Paris, France; the Baylor College of Medicine in Houston, Texas; and the
Seattle Children’s Hospital. All animal studies were conducted according to
the National Institutes of Health guidelines and regulation and de-identified
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with the Institutional Animal Care and Use Committee-approved protocols of
SJCRH, Fred Hutchinson Cancer Center, and Baylor College of Medicine.
The care and use of animal studies in Orsay, France were performed by strictly
applying European and National Regulation in force for the Protection of Verte-
brate Animals used in experimental and other scientific purposes (directive 86/
609). The protocol also complied with internationally established 3R principles,
in accordance with United Kingdom Coordinating Committee on Cancer
Research guidelines.
Cell Culture
Mouse and human G3 MBs, mouse SHH MBs, and Trp53-null GNPs were
grown as neurospheres in supplemented neurobasal medium, as described
previously (Kawauchi et al., 2012). HepG2 and TERT- BJ lines were purchased
from ATCC (#77400, CRL-4001) and human neural stem cells (H9) from
Invitrogen.
High-Throughput Screen
The SJCRH ‘‘bioactive’’ library consisted of 7,389 compounds (6,568 unique)
that were screened on mouse G3 MB and Trp53-null neurospheres. The HTS
was performed at one 10 mM concentration and the luminescent signal from
the plates were read 72 hr after treatment using CellTiter-Glo, as described
previously (Atkinson et al., 2011). Dose-response experiments identified 35
FDA-approved drugs from which three, decitabine, pemetrexed and gemcita-
bine, were chosen for further analysis. Additional details concerning the chem-
ical library screened, the HTS assay protocol, the hits validation and data
analysis, and ‘‘washout’’ experiments are reported in the Supplemental Exper-
imental Procedures.
Pharmacological Studies
Murine plasma and tECF samples were analyzed for pemetrexed and gemci-
tabine using separate validated liquid chromatography-tandem mass spec-
troscopy assays. To assay gemcitabine samples, tetrahydrouridine was
added during sample collection to prevent deamination of gemcitabine to
20,20-difluorodeoxyuridine by cytidine deaminase. For pemetrexed and gemci-
tabine plasma pharmacokinetic (PK) studies, a serial sacrifice plasma-only PK
study (single sample per mouse) was performed in tumor-bearing mice to
obtain initial plasma PK parameter estimates. These estimates were used to
inform a D-optimal, limited sampling model for microdialysis experiments,
minimizing bloodwithdrawal andmaximizing information content. Using a pre-
viously published microdialysis technique (Zhuang et al., 2006), we assessed
pemetrexed and gemcitabine tumor penetration separately in orthotopically
implanted mouse G3 MBs. Prior to the in vivo microdialysis study, microdial-
ysis probe recovery was assessed for each compound using an in vitro
recovery technique. More details on pemetrexed and gemcitabine liquid chro-
matography-tandem mass spectroscopy bioanalytical assays, plasma PK
studies, and cerebral microdialysis studies are described in the Supplemental
Experimental Procedures.
Statistical Analysis
Statistical analyses were performed in the GraphPad Prism software version
5.0. The Kaplan-Meier (log rank) test was used for testing significant mouse
survival.
Gene Expression Profiling
Total RNA was extracted using Trizol, as previously published (Kawauchi
et al., 2012). RNA was subjected to Affymetrix Gene Chip analysis
(HT430PM, Affymetrix). Data were analyzed with Spotfire (Kawauchi et al.,
2012) and for gene set enrichment analysis (Broad Institute). Gene ex-
pression of xenografts TB-12-5950 and Icb-1572 were compared to gene
expression profiles from 72 primary human medulloblastoma samples (Rob-
inson et al., 2012). Total RNA was extracted from the snap-frozen human
MBs and xenograft samples using STAT-60. mRNA profiles were generated
using U133 Plus 2.0 microarray (Affymetrix). The data were imported into
Spotfire Decision Site, and for each probe set and subject, Z scores were
calculated by computing the mean and SD across subjects within each
probe set.Immunoblotting, In Vivo BrdU Incorporation, Caspase 3 and BrdU
Immunostaining, Gamma-H2AX, and Fluorescence In Situ
Hybridization Analysis
All procedures and reagents are described in detail in the Supplemental Exper-
imental Procedures.
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